Vanqua Bio’s Post

Johnson & Johnson's experimental autoimmune drug, nipocalimab, demonstrated success in a Phase 3 study for treating generalized myasthenia gravis, offering significant benefits compared to a placebo. The drug works by targeting disease-causing antibodies, leading to improved daily functioning and quality of life for patients. J&J is optimistic about the potential approval of nipocalimab for this condition and aims to expand its usage across multiple indications, projecting substantial revenue growth. #AutoimmuneDisease #Nipocalimab #MyastheniaGravis #AntibodyTherapy #HealthcareInnovation Read more here: https://lnkd.in/egiNWQNN BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

Available on Healio CME: "Macular Telangiectasia: Shining a Light on Pathophysiology, Diagnosis, and Disease Burden" with Diana Do, MD and Arshad M. Khanani, MD, MA, FASRS. In this CE monograph, expert faculty describe the pathophysiology and burden of macular telangiectasia (MacTel) on patient quality of life and assess the diagnostic modalities that can improve early detection of the disease. Participate Today: https://lnkd.in/eHHdx3yf This activity is supported by an educational grant from Neurotech Pharmaceuticals, Inc.

Proud to have contributed together with Charlotte Hoogstraten en Frans Russel to our review about the drugability of mitochondrial carrier proteins, which is just published! In this review we provide an overview of the physiological function of these carrier proteins and challenges to asses their function. Next, we show how they are associated with a vast amount of pathologies. Finally, a total of 75 unique drug carrier interactions are described, which can either be classified as carrier inhibition, mitochondrial drug uptake or efflux. https://lnkd.in/em_Q7WqP #mitochondrialcarriers #subcellularpharmacokinetics #drugtransporters

Custom Tools for GIP Receptor Internalization and Biased Signalling Studies. Our latest case study highlights the development of stable cell lines using NanoLuc® Binary Technology (Promega) to measure real-time receptor-β-Arrestin interactions. This innovative approach provides deeper insights into GPCR activation and potential therapeutic strategies for metabolic diseases. https://lnkd.in/ev_Nnhfy #GIPReceptors #GPCR #CellLineGeneration #SBDrugDiscovery #SygnatureDiscovery

Check out this great news from our portfolio company, Hope Medicine Inc! The company's monoclonal antibody drug, HMI-115, which holds global rights, has been granted Breakthrough Therapy Designation (BTD) by the CDE of the NMPA. This designation is for the treatment of moderate to severe pain associated with endometriosis. The CDE's recognition is based on promising interim results from an ongoing global Phase 2 clinical trial. This randomized, double-blind, placebo-controlled study includes 142 women with endometriosis across the US, Poland, and China, led by Peking Union Medical College Hospital in China. Among the 102 patients included in the interim analysis, HMI-115 showed significant improvement in endometriosis-related pain with a strong safety profile. Most patients reported normal menstruation, and there were no significant changes in bone density or hormone levels. #Biotech #Innovation #BreakthroughTherapy #Endometriosis #ClinicalResearch #WomensHealth #MedicalAdvancements #DrugDevelopment #GlobalHealth #NMPA #BTD #QimingPortfolio #QimingHealthcare

Sebia #FLC are the first EIA tests receiving 510(k) from the #FDA for the quantitative detection of both #kappa and #lambda free light chains in human serum specimens, intended for both aid of diagnosis and monitoring of Multiple #Myeloma and Immunoglobulin Light-Chain (AL-) amyloidosis.  Click to learn more. #sebiausa #Freelightchain #multiplemyeloma #alamaloidosis

Did you know metabolic dysfunction-associated steatohepatitis (MASH) is caused by an excess of fat cells in the liver? Our drug candidate for MASH, entering Phase 2a clinical trials this year, has the potential to be best-in-class based on recent data we presented. Learn more here: https://brnw.ch/21wHuxk

Members of the GRI Bio, Inc. management team discuss the encouraging preclinical data that was recently presented and #whatthismeans for its #IPF program and #SLE development programs. https://lnkd.in/eDa8WtjJ #NKT # IdiopathicPulmonaryFibrosis #SystemicLupusErythematosus

Bristol Myers Squibb Presents the Long-Term P-III (MAVA-LTE) Trial Data of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) #bms #camzyos #symptomaticobstructivehypertrophiccardiomyopathy #clinicaltrial #phase3 #mavalte

As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more: